Satraplatin

  • (OC -6- 43) -bis ( acetato -O) ammindichloro (cyclohexylamine ) platinum
  • JM216

L01XA04

Cytostatic

Complex formation

Template: Infobox chemical / molecular formula search available

Satraplatin is the first platinum (IV ) complex, which finds application in tumor therapy. In contrast to the authorized platinum (II ) complexes such as Cisplatin, satraplatin has a higher lipophilicity, is relatively inert and is absorbed in sufficient amounts from the gastrointestinal tract, so that it can be administered orally. Is applied satraplatin for hormone prostate cancer, ovarian cancer and lung cancer that are not treatable with cisplatin. The cytotoxic effect is due to covalent bonds with the DNA of the cancer cells, which result in a retention of the cell cycle in G2 phase and eventually to apoptosis. Before interaction with the DNA of the platinum ( IV) complex by reduction of the active platinum is transferred (II ) form. Satraplatin is therefore a prodrug. The plasma half-life is 12 hours.

Satraplatin was developed by the pharmaceutical company Agennix.

CAS registry number PubChem Anatomical Therapeutic Chemical Classification System Cytotoxicity GPC Biotech Clinical Cancer Research Digital Object Identifier
710116
de